polyacrylamide
Small moleculeexperimental
Polyacrylamide (abbreviated as PAM or pAAM) is a polymer with the formula (-CH2CHCONH2-). It has a linear-chain structure. PAM is highly water-absorbent, forming a soft gel when hydrated. In 2008, an estimated 750,000,000 kg were produced, mainly for water treatment and the paper and mineral industries. — Wikipedia
Clinical trial activity
9 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
1
Earliest trial started May 16, 2001 (NCT00016536)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPolyacrylamide ↗
- ChEMBLCHEMBL2108995 ↗
- WikipediaAcrylic acid ↗
Also known as
- amazingel
- blephagel
- carbomer
- carbomer
- carbomer
- carbomer
- carbomer 910
- carbopol
- carbopol
- carbopol
- carbopol 910
- carbopol 910
- carbopol 974
- carbopol 980
- carboxypolymethylene
- duracryl liquid acrylamide
- hpa-i
- hpa-v
- poly(aam)
- polyacrylamide
- polyacrylamide
- polyacrylamide
- polyacrylamide aes-10
- polyacrylamide aes-5
- polyacrylamide aes-7
- polyacrylamide p100
- polyacrylamides
- rhinohide liquid acrylamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03997851 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2019 | University of Miami |
| NCT03005067 | Phase 2 | Dec 29, 2016 | GlaxoSmithKline |
| NCT02992392 | N/A | Dec 1, 2016 | Sun Yat-Sen University |
| NCT02832362 | Phase 1 | Jun 11, 2016 | GlaxoSmithKline |
| NCT02077231 | N/A | Sep 1, 2011 | Fudan University, Shanghai Jinshan Hospital |
| NCT01375582 | Early Phase 1 (Phase 1) | Jun 1, 2011 | Bausch & Lomb, University of Rochester |
| NCT01563172 | Phase 4 | Jan 1, 2009 | GlaxoSmithKline |
| NCT00637962 | Phase 1 | Sep 1, 2007 | Bill and Melinda Gates Foundation, University of London, York University |
| NCT00016536 | Phase 1 | May 16, 2001 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 3 | 2009 |
| Bausch & Lomb | For profit | 1 | 0 | 1 | 2011 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2001 |
| Shanghai Jinshan Hospital | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2007 |
| University of Miami | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2011 |
| York University | Academic/Hospital | 1 | 0 | 1 | 2007 |
11 organizations
Page 1 / 1